AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Datroway (datopotamab deruxtecan by Quarter
Datroway (datopotamab deruxtecan — direct product sales) — Established RoW product sales ($M) ($M)
AstraZeneca Datroway (datopotamab deruxtecan: $0M in Q2 2026.
Where the Q2 2026 figure comes from
“|| Datroway | | 4 | | n/m | | n/m | | - | | - | | 4 | | n/m | | n/m | | - | | - | | - | | - | | - | | -”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Datroway (datopotamab deruxtecan — direct product sales) — Established RoW product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 0 | – | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 0 | – | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 0 | – | Form 6-K FY2025Q4 Earnings Release ↗ |
Breakdown
What makes up datroway (datopotamab deruxtecan
Cite this data
StockData. (2026). AstraZeneca Datroway (datopotamab deruxtecan ($M), quarterly Q4 2025–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-datroway-erow
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.